Disclosures for "Response to Next Intervention After Off-label Ivosidenib Treatment Failure in Patients With Mutant IDH Low Grade Glioma"
-
Dr. Minor has nothing to disclose.
-
Dr. Zhang has received personal compensation for serving as an employee of Daiichi Sankyo (China) Holding Co., Ltd..
-
Author has nothing to disclose
-
Dr. Dewey has received personal compensation for serving as an employee of Servier Pharmaceuticals.
-
Dr. Patel has nothing to disclose.
-
Miss Savelli has nothing to disclose.
-
Dr. Johnson has nothing to disclose.
-
Kristen Batich has nothing to disclose.
-
Dr. Low has nothing to disclose.
-
Dr. Shoaf has nothing to disclose.
-
Author has nothing to disclose
-
Dr. DesJardins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Orbus Therapeutics. Dr. DesJardins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biodexa. Dr. DesJardins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Telix Therapeutics. Dr. DesJardins has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Chimerix. Dr. DesJardins has stock in Istari Oncology. Dr. DesJardins has received intellectual property interests from a discovery or technology relating to health care.
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Mrs. Calabrese has nothing to disclose.
-
Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Servier. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sapience. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ONO Pharmaceutical. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Telix. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AnHeart. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rigel. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Nuvation. The institution of Dr. Peters has received research support from Biomimetix. The institution of Dr. Peters has received research support from Servier. The institution of Dr. Peters has received research support from Varian. The institution of Dr. Peters has received research support from Sapience. The institution of Dr. Peters has received research support from Ono Pharmaceuticals/Deciphera. The institution of Dr. Peters has received research support from Nuvation. The institution of Dr. Peters has received research support from Novocure. The institution of Dr. Peters has received research support from Curis.